Baidu
map

巴西期刊GMR回应“洋野鸡”质疑:质量责任交给作者

2016-09-28 记者林小春 新华社

美国“剽窃监督”网站日前曝光巴西杂志《遗传学和分子研究》(GENET MOL RES)刊登一些来自中国、疑似由“枪手”炮制的论文,质疑其是一份旨在敛财的“洋野鸡”杂志(详细见:深度揭密论文造假背后:有人的地方就有江湖)。该杂志26日对新华社记者回应称,最好的学术期刊也不能幸免发表剽窃文章,因此他们把论文的真实性与质量的把关责任交给了作者。记者发现,这一说法与科学论文主要出版商长期以来坚持的同行评议

美国“剽窃监督”网站日前曝光巴西杂志《遗传学和分子研究》(GENET MOL RES)刊登一些来自中国、疑似由“枪手”炮制的论文,质疑其是一份旨在敛财的“洋野鸡”杂志(详细见:深度揭密论文造假背后:有人的地方就有江湖)。该杂志26日对新华社记者回应称,最好的学术期刊也不能幸免发表剽窃文章,因此他们把论文的真实性与质量的把关责任交给了作者(小编注:这背后的话中话是什么?)。

记者发现,这一说法与科学论文主要出版商长期以来坚持的同行评议制度相违背。

所谓同行评议是学术刊物普遍采用的一种论文评审制度。一般由刊物编辑邀请论文所涉领域的学者,评价论文质量,主编参考评议结果决定是否刊发。无论是《科学》《自然》这样传统的学术期刊,还是论文作者付费刊用、读者可免费获取的主流开放获取期刊,在发表论文前都会让同一领域的其他专家加以评议,从而保证论文质量。

《遗传学和分子研究》回应说,近几年来自亚洲特别是中国年轻研究人员提交的论文数量大幅增加。“我们认为,这种增长是因为发展中国家的资助机构与教育机构要求研究人员在被索引期刊上快速发表更多论文”,但国际期刊数量有限,无法发表这么多论文。

回应辩称,《遗传学和分子研究》刊登的论文数量之所以增加,是因为该杂志持有的出版理念是,论文真实性与质量的把关责任应更多交给论文作者。该杂志认为,研究人员职业生涯最重要的一个方面就是他们的声誉,冒着声誉风险发表低质量研究或剽窃论文将伤害科学进步,并对他们的职业发展造成极大伤害,“因此我们的评审过程把这些方面(真实性与质量)的责任交给了作者”。

回应说:“一旦发现(已经发表的)‘坏’论文,有证据表明这篇论文存在虚假数据或剽窃,那么论文就会被撤回,而期刊将发出撤回通知。”回应还表示,该杂志将把有关发现通知论文作者的所在单位。

《遗传学和分子研究》被收录在汤森路透集团的科学引文索引(SCI)数据库中。此前,该机构一名发言人对新华社记者说,将对有关杂志进行调查,可能会将其从SCI数据库中除名。

被科研界统称为SCI的科学引文索引,已有50多年历史。实际上它是一个庞大的引文数据库,通过科研论文被引用的频次来体现科研成果和学术期刊的影响力。科研界通常所说的SCI期刊,就指被其数据库所收录的学术期刊,每年这些期刊都有相关的影响力因子排名。

随着近些年开放获取期刊的兴起,加上中国有关人员发表论文的现实需求,国外一些学术出版商利用这种“作者付费、读者免费”的出版模式,从中获取暴利。谨防“洋野鸡”学术期刊到中国来混水捞金,已成为一个迫在眉睫的严重问题。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1735082, encodeId=0c021e35082f4, content=<a href='/topic/show?id=9aa5923e176' target=_blank style='color:#2F92EE;'>#质疑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92371, encryptionId=9aa5923e176, topicName=质疑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d3033872914, createdName=saikp, createdTime=Fri May 26 15:46:00 CST 2017, time=2017-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580832, encodeId=134a1580832a3, content=<a href='/topic/show?id=cc274831170' target=_blank style='color:#2F92EE;'>#巴西#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48311, encryptionId=cc274831170, topicName=巴西)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81dd16663079, createdName=ms9833124466084992, createdTime=Fri Sep 30 04:46:00 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137355, encodeId=a3e913e3557d, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 21:53:05 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137348, encodeId=851713e34809, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 21:32:59 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137347, encodeId=680713e34706, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 21:32:49 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137084, encodeId=41c113e084aa, content=都有自己的说法啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Sep 28 18:01:06 CST 2016, time=2016-09-28, status=1, ipAttribution=)]
    2017-05-26 saikp
  2. [GetPortalCommentsPageByObjectIdResponse(id=1735082, encodeId=0c021e35082f4, content=<a href='/topic/show?id=9aa5923e176' target=_blank style='color:#2F92EE;'>#质疑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92371, encryptionId=9aa5923e176, topicName=质疑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d3033872914, createdName=saikp, createdTime=Fri May 26 15:46:00 CST 2017, time=2017-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580832, encodeId=134a1580832a3, content=<a href='/topic/show?id=cc274831170' target=_blank style='color:#2F92EE;'>#巴西#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48311, encryptionId=cc274831170, topicName=巴西)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81dd16663079, createdName=ms9833124466084992, createdTime=Fri Sep 30 04:46:00 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137355, encodeId=a3e913e3557d, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 21:53:05 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137348, encodeId=851713e34809, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 21:32:59 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137347, encodeId=680713e34706, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 21:32:49 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137084, encodeId=41c113e084aa, content=都有自己的说法啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Sep 28 18:01:06 CST 2016, time=2016-09-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1735082, encodeId=0c021e35082f4, content=<a href='/topic/show?id=9aa5923e176' target=_blank style='color:#2F92EE;'>#质疑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92371, encryptionId=9aa5923e176, topicName=质疑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d3033872914, createdName=saikp, createdTime=Fri May 26 15:46:00 CST 2017, time=2017-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580832, encodeId=134a1580832a3, content=<a href='/topic/show?id=cc274831170' target=_blank style='color:#2F92EE;'>#巴西#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48311, encryptionId=cc274831170, topicName=巴西)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81dd16663079, createdName=ms9833124466084992, createdTime=Fri Sep 30 04:46:00 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137355, encodeId=a3e913e3557d, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 21:53:05 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137348, encodeId=851713e34809, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 21:32:59 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137347, encodeId=680713e34706, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 21:32:49 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137084, encodeId=41c113e084aa, content=都有自己的说法啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Sep 28 18:01:06 CST 2016, time=2016-09-28, status=1, ipAttribution=)]
    2016-09-28 知难而进

    继续关注!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1735082, encodeId=0c021e35082f4, content=<a href='/topic/show?id=9aa5923e176' target=_blank style='color:#2F92EE;'>#质疑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92371, encryptionId=9aa5923e176, topicName=质疑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d3033872914, createdName=saikp, createdTime=Fri May 26 15:46:00 CST 2017, time=2017-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580832, encodeId=134a1580832a3, content=<a href='/topic/show?id=cc274831170' target=_blank style='color:#2F92EE;'>#巴西#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48311, encryptionId=cc274831170, topicName=巴西)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81dd16663079, createdName=ms9833124466084992, createdTime=Fri Sep 30 04:46:00 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137355, encodeId=a3e913e3557d, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 21:53:05 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137348, encodeId=851713e34809, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 21:32:59 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137347, encodeId=680713e34706, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 21:32:49 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137084, encodeId=41c113e084aa, content=都有自己的说法啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Sep 28 18:01:06 CST 2016, time=2016-09-28, status=1, ipAttribution=)]
    2016-09-28 知难而进

    继续关注!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1735082, encodeId=0c021e35082f4, content=<a href='/topic/show?id=9aa5923e176' target=_blank style='color:#2F92EE;'>#质疑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92371, encryptionId=9aa5923e176, topicName=质疑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d3033872914, createdName=saikp, createdTime=Fri May 26 15:46:00 CST 2017, time=2017-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580832, encodeId=134a1580832a3, content=<a href='/topic/show?id=cc274831170' target=_blank style='color:#2F92EE;'>#巴西#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48311, encryptionId=cc274831170, topicName=巴西)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81dd16663079, createdName=ms9833124466084992, createdTime=Fri Sep 30 04:46:00 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137355, encodeId=a3e913e3557d, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 21:53:05 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137348, encodeId=851713e34809, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 21:32:59 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137347, encodeId=680713e34706, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 21:32:49 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137084, encodeId=41c113e084aa, content=都有自己的说法啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Sep 28 18:01:06 CST 2016, time=2016-09-28, status=1, ipAttribution=)]
    2016-09-28 知难而进

    谢谢分享!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1735082, encodeId=0c021e35082f4, content=<a href='/topic/show?id=9aa5923e176' target=_blank style='color:#2F92EE;'>#质疑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92371, encryptionId=9aa5923e176, topicName=质疑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d3033872914, createdName=saikp, createdTime=Fri May 26 15:46:00 CST 2017, time=2017-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580832, encodeId=134a1580832a3, content=<a href='/topic/show?id=cc274831170' target=_blank style='color:#2F92EE;'>#巴西#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48311, encryptionId=cc274831170, topicName=巴西)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81dd16663079, createdName=ms9833124466084992, createdTime=Fri Sep 30 04:46:00 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137355, encodeId=a3e913e3557d, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 21:53:05 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137348, encodeId=851713e34809, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 21:32:59 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137347, encodeId=680713e34706, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 21:32:49 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137084, encodeId=41c113e084aa, content=都有自己的说法啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Sep 28 18:01:06 CST 2016, time=2016-09-28, status=1, ipAttribution=)]
    2016-09-28 oo902

    都有自己的说法啊

    0

相关资讯

SciEngine: 助力中国科技期刊走向国际

2016年4月18日,由《中国科学》杂志社自主研发的SciEngine平台(engine.scichina.com)开始试运营。SciEngine以《中国科学》系列和《科学通报》的内容资源为依托,是我国首个集全流程数字出版与国际化传播于一体的科技期刊服务平台。     当前国际科技期刊数字出版技术飞速发展,出版商不仅拥有内容丰富的电子期刊资源,而且能够提供越来越多

国际期刊以学术之名敛财 被曝登中国造假论文

近日,美国反论文抄袭网站“剽窃监督”根据网友举报,从调查一篇剽窃的论文入手,顺藤摸瓜获得惊人发现:一些旨在敛财的“掠食性”国际学术期刊与代写论文的“枪手”公司狼狈为奸,疑似为大批中国研究人员批量生产、发表学术论文。该网站编辑告诉本报记者,他们发现的可能是世界科学历史上国外学术出版商瞄准中国研究人员敛财的“最大丑闻”。负责运营SCI(科学引文索引)数据库的汤森路透集团说,将对有关学术期刊进行调查

一个开放获取索引移除数千期刊

一个开放获取期刊索引缩水超过1/4,约3300份期刊被移除,以整顿可疑和不活跃出版商。今年年初,开放获取期刊目录(DOAJ)收录了1.1万多份开放获取学术期刊,之后它宣布将收紧收入标准。它要求收录的期刊提供更多运行细节,以确保这些期刊按照基本出版规定操作。该目录曾因包含“掠夺性出版商”而备受指责。这些期刊声称开放获取,但常收取附加费用,它们或直接欺骗读者,或提供的服务达不到预期,例如只有最低标准的

OA收录系统整治减掉期刊3300种,黑名单发布

· 导语 · 自从OA期刊收录系统加强了质量管理标准,许多OA期刊就不再适合收录了。DOAJ经过排除问题期刊和不活跃的期刊后,缩减了约四分之一,3300种期刊。 在两年前,DOAJ约有11,000个学术期刊, 同年DOAJ宣布严格控制其入库标准,要求每个杂志提供其基本操作以便保证它们遵循基本的出版标准。结果出来后,DOAJ被指包含有“掠夺

《全球健康研究与政策》期刊推出

科学、技术、医学出版机构生物医学期刊出版中心(BioMed Central)6月16日携手中国武汉大学全球健康研究中心,推出多学科同行评审的开放获取期刊《全球健康研究与政策》。该刊旨在发表高质量的科研论文,以改善区域及全球健康状况并促进健康公平。 “当前,关于全球健康的这门学科尚处于早期阶段,但有望迅速发展起来,《全球健康研究与政策》期刊为科研人员、教授及研究生提供了一个交流思想和科研成果

非法期刊的辨别方法,发文章的必看!

近年来,在我国学术评价体系中,论文发表情况作为一个最基本的评价要求引起大家的广泛重视,评职称、科研业绩考核、取得学位等都需要在期刊上发表论文。而正规期刊容量有限,广大作者缺少论文发表的足够空间或者由于论文质量欠佳难以发表,这在一定程度上给非法期刊留出了空间。为此,我国政府有关部门加大了监管、查处和取缔的力度,新闻出版总署、全国“扫黄打非”工作小组办公室自2004年7月以来已经连续公布了四批共169

Baidu
map
Baidu
map
Baidu
map